Life Sciences Archive » August, 2022

Life Sciences - August, 2022

340 articles

• Delay Tactic May Be Outcome Of DC Circ.'s FCA Liability Rule
• Canadian Pot Co. Investors Win Class Cert. In Acquisition Suit
• Calif. Stem Cell Clinic Isn't Subject To FDA Rules, Judge Says
• Inflation Reduction Act Paves Way For Drug Pricing Reform
• 3rd Circ. Nixes Sanctions Over Lab's 'Aggressive' Actions
• ABA Stance On Role Of Nonlawyers Is Too Black And White
• The Fed. Circ. In August: Considerations In Assignor Estoppel
• 5th Circ. Ruling Highlights Split On Ch. 11 Exculpation
• Philips To Pay $4M Over Claims It Skirted Military Testing Rule
• Clariant To Sell Chemical Biz To Own Joint Venture For $113M
• FDA Clears The Way For Moderna, Pfizer Omicron Boosters
• Sterigenics Rep Says It Didn't Need To Warn Of Emission Risk
• Feds Rip Exec's 'Culture Of Lies' As COVID Fraud Trial Wraps
• NY AG Wants Info On CVS, Walgreens Reproductive Care
• Eli Lilly Verdict Offers Insight Into FCA Scienter Battle
• Mississippi Diabetes Treatment Price Suit Mostly Survives
• Fla. Lab Owner Charged In NJ With $53M Medicare Fraud
• Iancu Downplays Patent Counts For Measuring IP Competition
• Investors Spar Over Ionis Director Pay Suit Deal In Chancery
• Firm Yanks Atty From Ga. Clinic FCA Suit After DQ Bid
• Medical Providers Must Brace For More DOJ Opioid Probes
• Harnessing The Power Of Big Data In Litigation
• Del. Jury Awards $2.3M Over Bone Imaging IP Infringement
• Gov't Denies Liability For Radioactive Injury Indemnity
• Judge Trims Some State Law Antitrust Claims From Lye Suit
• Roche Loses Appeal Against Generic Co. At China's Top Court
• Hartford Loses Bid To Undo Deal In MRI Explosion
• CR Bard Owes $4.8M To Hernia Mesh Patient, Jury Says
• FTC Brings Privacy Suit Against Co. Challenging Its Authority
• High Court Told Gov't Gave Up Chance To Dismiss FCA Case
• How Law Firm Operations Can Adjust To New COVID Realities
• J&J Fraud Suits Can Continue Despite Imerys Ch. 11 Stay
• Olympus Sells Microscope Biz To PE Firm In Nearly $3.1B Deal
• 'Wrong Message' To Free Ex-Insys Exec Early, Judge Says
• Med Tech Co. Says Ex-Worker Swiped Trade Secrets For Rival
• NY Law Firm Hit With Malpractice Suit By Health Care Co.
• J&J Must Face Pelvic Mesh Suit After 6th Circ. Reversal
• Formulation Patent Strategies Carry Untapped Potential
• O'Melveny Adds Longtime Life Sci IP Litigator From Honigman
• GrayRobinson Adds Ex-Morgan & Morgan Atty In Orlando, Fla.
• 3 Questions As Moderna Wages COVID Patent Attack On Pfizer
• Sterigenics Could Have Cut Toxic Emissions Earlier, Jury Told
• Assessing The Criminal Implications Of State Abortion Bans
• Fed. Circ. Affirms PTAB Ax Of Cancer Screening Claims
• Carestream Gets Approval For $85M Ch. 11 Exit Loan Deal
• Food, Drug, Cosmetic Cos. Should Expect More Additive Suits
• 4 More Small IPOs Tap Public Markets For $62M Combined
• Convicted Seller Of Racehorse PEDs Asks For No Prison
• Law Of The Case Is More Nuanced Than You May Think
• Don't Miss It: Skadden, Kirkland Guide Week's Hot Deals
• UK Litigation Roundup: Here's What You Missed In London
• Moderna Lobs COVID Vaccine IP Suit At Pfizer, BioNTech
• 9th Circ. Gives Allergan 2nd Chance To Ax FCA Suit
• Gilead Fights High Court Bid Over 'Possession' Of Invention
• Genomics Co. Parse Targeted In Patent Suit From 10x
• Tepezza Label Silent On Serious Hearing Risks, Suit Says
• Engage Associates At Orientation With Thoughtful Activities
• 8th Circ. Says Biomet Received A Fair Trial In Hip Implant Suit
• NJ Justices Toss Punitive Claims Over FDA Device Warning
• Centene Strikes $33M Deal To End Wash. Medicaid Fraud Suit
• Wilson Sonsini Adds Former In-House Atty To New York Office
• Gilead Sciences Owes $2M Sponsor Fee For Canceled Series
• Novartis To Spin Off $9.6B Sandoz Generic Drugs Biz
• COVID-19 Tort Cases Have Peaked, Report Says
• Idaho Blocked From Enforcing Abortion Ban In Emergencies
• Ex-Clinic Exec Asks Judge To Disqualify Counsel In FCA Suit
• Health Issues To Watch In Inflation Act, Other Policy Initiatives
• Small IPOs Buck Trends In An Otherwise Cold Market
• Evidence Rule Changes Help Judges Police Expert Testimony
• Court Lets Carestream Tap $50M, Tells Exit Lenders To Wait
• Texas Prosecutors Face Abortion Ban Enforcement Challenge
• Clark Love Sued Over 'Scheme' To Settle Expired Mesh Suits
• A Federal Data Privacy Law Is The Disaster We Urgently Need
• Texas Wins Halt Of HHS' Emergency Abortion Care Guidance
• The Cruciality Of Building Client Intimacy Ahead Of Recession
• Bard Tells Mesh Jury Patient Didn't Prove What He Promised
• 11th Circ. Says FDA Must Weigh Youth Vape Restriction Plans
• Inovio Inks $44M Cash, Stock Deal To End COVID-19 Vax Suit
• 5 Amici Back Drug Cos. Fighting Denial Of Patent Review
• Foley Snags Antitrust Partner From Colo. AG's Office
• Ch. 11 Cheat Sheet: Carestream Health Inc.
• Curaleaf Renews Quest To End Workers' Stolen Tips Suit
• Essilor Will Pay $22M To End Doctor Kickback Claims
• How To Win Over Bench Trial Judges Post-COVID
• Ex-Vitamin Shoppe CFO's Retaliation Claims Tossed In NJ
• Becton Dickinson Gets Drug Transfer System IP Suit Tossed
• Medical Imaging Co. Carestream Hits Ch. 11 With $1B Of Debt
• These Firms Have The Most Women In Equity Partnerships
• Indivior Loses Bid For Early Win In 'Product Hop' MDL
• Pharmacies Can't Be Forced To Fill Ivermectin Rx, Judge Says
• Court Won't Block Plan To Sell Cloned Polo Horses
• Vaxart Investors Seek Initial OK Of $12M Deal In Fraud Suit
• Ex-Amarin Pharma Exec Denied Quick Win Over Noncompetes
• PTAB Denies Chinese Co.'s IPR Targeting Cultured Cell Patent
• Anti-Abortion Activists Lose At 9th Circ. In Video Row
• Bayer AG CEO Ordered To Testify In Roundup Case
• Endo Unit Seeks To Stop Termination Of Drug License Deal
• Actavis Can Deduct $12M In Legal Fees, Claims Court Says
• J&J Talc Unit Gets Nonprofit Assist In Fight To Keep Ch. 11
• Pay Expert Cops To Taking Illegal $400K Insider Payday
• A Cautionary Tale On Diversity Jurisdiction From The 6th Circ.
• High Court Wants Gov't View On Controversial FCA Case
• Quest's Virus Row Stays In Wash. As AIG's NJ Suit Is Tossed
• Catching Up With Delaware's Chancery Court
• Medical Imaging Startup Soars In Shanghai After Smash IPO
• Judge Rejects Bid Protections For GenapSys Stalking Horse
• Ex-MiMedx Execs Can't Undo Fraud Convictions At 2nd Circ.
• A Deep Dive Into The Glass Ceiling Report: Women In Law
• Monsanto Mgr. Tells Jury Roundup Study Edits 'Suggestions'
• NY Court Told It Can't Ax Swiss Medical Imaging Award
• GSK Says Teva's Skinny-Label Row Is 'No Threat' To Generics
• Insuring Psychedelic Therapy Key To Promising Industry
• Don't Miss It: Goodwin, Cooley Guide Week's Hot Deals
• Medical Supply Co. Gets $5M In Nursing Home Fraud Case
• EFF Says Tillis Bill Would Bring Back 'Worst Patent Abuses'
• Judge Denies Ch. 11 Dismissal Try By GenapSys Founders
• Colo. Pharma Co. Faces Securities Suit Over Drug Claims
• Former Amarin Exec's Noncompete Brawl Likely Not Over Yet
• Overly Broad PFAS Regs Bring Costs For Companies
• Stockholder Sues Pharma Co. For Docs On $149M Merger
• A Jump Forward For Fla. Pharmacy Technicians' Vax Authority
• Drug Impairment Testing Deemed Reliable In NJ Case
• Goodwin-Guided Kymera Raises $150M With Share Sale
• DOJ Filing Reawakens Fraud-On-The-FDA Theory Of Liability
• Australian Beverage Co. Plans To Tap US Market For $20M IPO
• UK Litigation Roundup: Here's What You Missed In London
• Sterigenics Polluted Ill. Village For Decades, Jury Hears
• Lanier On $650M Opioid Win: I'd Have Settled For 'A Lot' Less
• Endo Noteholders Say Alternative Ch. 11 Plan Needed
• Nicotine Firm Gets First-Ever Warning For Marketing Gummies
• Vidal Takes Up Boehringer's Failed Pig Vaccine IP Challenge
• Teva Found To Infringe Vifor Fresenius Kidney Drug Patent
• 3rd Circ. Denies Doc's Bid For New Trial In $100M Fraud Case
• Westco Gets Early Win In 'Secret' Pension Plan Suit
• Fed. Circ. OKs Eagle's Generic Vasostrict In Loss For Endo
• Using Bayh-Dole To Control Drug Prices Would Skew Statute
• Strategies For Improving Diversity In Psychedelics Research
• CBD Supplement Buyers, Maker Spar Over Resuming Suit
• Endo Beats Investors' Opioid Crisis Class Action, For Good
• Supplement Makers Reach Patent Deal After Amazon Fight
• 1st Circ. Says Dormant Commerce Clause Applies To Med. Pot
• Key Factors In Determining Specific Personal Jurisdiction
• Judge Axes IP Suit Over Xifaxan, Ruling The Drug Is Prior Art
• Surescript's EpiPen Citation 'Nothing New,' FTC Says
• J&J Talc Unit Defends 'Valid' Ch. 11 Filing At 3rd Circ.
• Zantac Plaintiff Dismisses Suit 1 Week Before Trial
• 6th Circ. Refuses To Double Atty Fees From Pharmacy's Ch. 7
• Paul Hastings Tech M&A Pro Joins Baker Botts In Palo Alto
• Del. Suit Alleges Insider Trades Worth $171M By Nektar Execs
• Orrick Adds Partner In Transactional Tax
• Longtime Hogan Lovells Partner Jumps To Mayer Brown In DC
• CVS, Walmart, Walgreens Owe $650M In Ohio Opioid Fallout
• Endo Hits Ch. 11 Amid Opioid Suit Crush
• 'Sea Change In The Law': Inside One Firm's Post-Roe Practice
• Software Biz Urges Fed. Circ. To Revive License Breach Deal
• Merck's Zetia Arguments Don't Misuse Privilege, Judge Says
• Co. Fights 'Serial Objector' Claim In Settlement Of Ad Case
• Idaho Co. Fights FTC's Suit Threat Over Data Tracking
• Biden Signs Landmark Tax And Climate Bill Into Law
• After NY Asbestos Rulings, Lung Cancer Suits Face Obstacles
• What Litigators Can Really Learn From Rambo
• Kirkland-Guided Thompson Street Closes $1.5B Fund
• Eton Infringes Preterm Infant Drug Patents, Del. Judge Rules
• Fed. Circ. Urged To Toss Pot Co.'s CBD Patent Appeal
• Mass. Health Network, Insurer Settle Over Scientist's Award
• 1st Circ. Partially Resurrects Azurity's Beef With Edge Pharma
• NY AG Rips 'Secret' Info From 'Besmirched' Arnold & Porter
• Okla. Court Fit For Cherokee Opioids Suit, 10th Circ. Told
• McKesson Hid Sales Data In FCA Suit, Whistleblower Says
• Justices Urged To Reject Review Of Biogen MS Drug IP Ruling
• Justices Told Generic Drugs At Risk From Skinny Label Ruling
• NCAA Hit With Concussion Class Action By Ex-FSU Player
• Catching Up With Delaware's Chancery Court
• Attorneys Should Note Judges' Financial Conflicts Of Interest
• Protein Products Recall For Deadly Germ Sparks Class Suit
• Joint Juice Maker Hit With $12.8M In Statutory Damages
• Ex-Virginia Assistant AG Joins Cozen O'Connor
• A Guide To Navigating Bankruptcy's Impact On IP Licenses
• Senate Cannabis Bill May Give Some Cos. A Competitive Edge
• Covington Hires Former FDA Atty From Sidley
• Monsanto Atty Grills Oncologist On Roundup Usage Numbers
• New Patent Bill Could Boost Diagnostics, But Needs Work
• Becton's Former CEO And CFO Escape Securities Suit
• Appalachia Opioid Charges Dropped After High Court Ruling
• Big Pharma Expected To Put Up Fight Over Drug Negotiations
• Enforcing Patents Isn't Easier As America Invents Act Turns 10
• House Sends Landmark Tax And Climate Bill To Biden
• Investors Sue Pharma Co. In Chancery Over Diabetes Drug
• Jones Day, Ropes & Gray Lead $950M HIG-Avient Deal
• Gordon & Rees Brings On Asbestos Expert In California
• Pa. Cannabis Banking Law Won't Allay Finance Industry Fears
• Pharma Exec Admits Lying To FDA About Weight-Loss Drug
• A Law Firm's Guide To Avoiding Client Conflicts
• Expect More DOJ Labor Market Enforcement, Despite Losses
• Nursing Homes Must Brace For Data-Driven DOJ Scrutiny
• Seagen Eyes $12M In Atty Fees On Top Of $42M Daiichi Verdict
• The Defense Bar Must Push Back On Social Inflation
• Health Hires: WelbeHealth, Enzo Biochem, CooperCompanies
• UK Litigation Roundup: Here's What You Missed In London
• Feds Aim For More Insight On Hacks With Maze Of Policies
• Calif.'s Broad Nuisance Law Key To Walgreens Opioid Liability
• Winless In Opioid Bouts, Will Pharmacies Throw In The Towel?
• J&J To Halt Global Talc Baby Powder Sales In 2023
• Full Fed. Circ. Won't Mull USPTO Interim Director's Powers
• W.Va. Reaches Opioid Deal With Rite Aid Worth Up To $30M
• Fed. Circ. Still Won't Let Minerva Invalidate Hologic Patent
• HHS Wants 3rd Circ. To Revive Drug Discount Violation Notice
• Montana High Court Blocks State's Anti-Abortion Laws
• Surgical Robot Co.'s Antitrust Fight Heads To Dec. Trial
• 5th Circ. Backs CR Bard Win Over Vein Filter Implant Design
• Viatris Asks Fed. Circ. To Revive Hypertension Drug IP Fight
• Anti-Kickback Circuit Split Holds Implications For Defendants
• Judge Issues Mixed Ruling In Salix, Norwich Patent Row
• Zicam Inventor Charged With 'I Love Lucy' TV Co. Scam
• Wilson Sonsini Lures IP Atty To Boulder, Eyes Colo. Growth
• Understanding DC Circ.'s Agency Rule Withdrawal Debate
• NJ Atty Booted From Pharma Co.'s Herbal Extract TM Row
• Garland Defends FBI, Moves To Unseal Trump Search Warrant
• Lessons For Federal Lawmakers As Calif. Alters Cannabis Tax
• Flint Case Ends In Mistrial After Jurors Cite Mental Health
• 9th Circ. Backs Arbitration Order In Tribe's Rx Payback Case
• Endo Teeters On The Edge, Revlon Equity Committee Sought
• Big Tobacco Wins 8th Delay Of Graphic New Warning Labels
• Skadden, Fried Frank Build $475M Sale Of Mayne Pharma Unit
• Considerations For Associates As Lateral Hiring Cools Down
• Allergan Must Comply With Implant MDL Discovery
• Rx Delivery Co. Prescribes Toss For Data Breach Suit
• Walgreens Fueled SF Opioid Epidemic, Judge Rules
• Sartorius To Acquire Albumedix For £415M
• Anti-Abortion Activists Ask 9th Circ. To Nix Videos Injunction
• Mylan Gets Industry Aid In $50M Tax Fight At 3rd Circ.
• Endo Says Bankruptcy Likely In Face Of Opioid Suits
• Amgen Looks To Duck Regeneron's Bundling Suit
• Latham, Kirkland Lead $718M Sale Of Huntsman's Textile Biz
• Chancery Splits Trial On Biopharma Co. Plasmid Supply Suit
• 7th Circ. View Of FCA Intent Is 'Deeply Flawed,' Justices Told
• Ionis Investor Seeks Fee For Director Pay Suit Deal In Del.
• Viatris Can't Keep Novo's Weight Loss Drug IP Suit In W.Va.
• NC Drugmaker Seeks OK Of Ch. 11 Deal With Distributor
• Feds Want Exec's Advice-Of-Counsel Fraud Defense Barred
• Flint Judge Steps Aside During Deliberations Due To Health
• Justices' EPA Ruling Didn't Move Needle On Chevron Doctrine
• Hemp Biotech Co. Aims To Nix Suit After 2nd Circ. Revival
• Actavis Keeps Trial Win In Man's Heart Attack Suit
• Exec Defrauded Medicare With COVID Test Lies, Jury Told
• Judge Trims Pfizer, Mylan EpiPen Antitrust Suit
• DOJ Says Medical Pot Patients Have No Right To Bear Arms
• Biopharma Co. Accused Of Lying To Investors About FDA Hold
• Trump Says FBI 'Raided' His Mar-A-Lago Resort
• Radius Health Investor Sues To Probe $890M Merger
• Eisai Wins Ax Of Sleep Drug Patent Claims At PTAB
• Mallinckrodt Noteholders Seek End To Default Payment Appeal
• Catching Up With Delaware's Chancery Court
• Health Co. Accused Of Stealing Psilocybin Therapy Idea
• 2nd Circ. Partially Revives Bausch Lens Case
• 3 Firms Shape Pfizer's $5.4B Deal For Sickle Cell-Drug Maker
• CVS Can't Escape HIV Patients' Disability Bias Suit
• Senate Sends Dems' Landmark Tax, Climate Bill To House
• Walmart, CVS, Walgreens Ask 10th Circ. To Pause Opioid Suit
• 1st Circ. Won't Revive Karyopharm Investors' Stock-Drop Suit
• Benicar Plaintiffs Appeal Axing Of Fee Suit To 3rd Circ.
• Landmark Opioid Opinion 'Not Persuasive,' W.Va. Panel Says
• After Dobbs: Kan. Voters, DOJ Fight Abortion Restrictions
• Scouts' Plan Mostly Approved, Jones Hit With $50M Verdicts
• Medtronic Inks Deal To End Faulty Pacemaker Suit
• Ethics Lessons From The Alex Jones Discovery Debacle
• Boston Scientific Reaches Deal To End Implant Death Suit
• The Role Of Morality In IP Suits Over COVID-19 Vaccines
• Profs Urge Full Fed. Circ. To Review 'Startling' Novartis Ruling
• Suits Over Tainted Abbott Baby Formula Join Illinois MDL
• Ex-FDA Veteran Joins Sidley In DC
• In-House At A Cannabis Company: The Advertising Issues
• Nixon Peabody Names Global Finance Co-Leaders
• Priest's Prayer For New Stock Fraud Trial Goes Unanswered
• UK Litigation Roundup: Here's What You Missed In London
• Monkeypox Deemed National Emergency As Cases Near 7,000
• Shareholders Lose Lawsuit Over Diabetes Drug Delay
• Cooley Atty Ordered To 'Personally Pay' For 'Hubris'
• Philips' IP Suit Over Ultrasound Co.'s Alleged Hacking Stands
• Feds Say Ex-Insys Executive Doesn't Deserve Early Release
• Gardasil Vax Suits Sent To North Carolina
• Wachtell, Latham & Watkins Steer $3.7B Biopharma Deal
• Farm Tells 4th Circ. Water Act Citizen Suit Should Get Boot
• 3rd Circ. Says Court Must Revisit Arbitration In OptumRx Case
• Agriculture Patent Reform Can Look To Pharma Approaches
• Dobbs, Workers' Comp. Brief Hint At Biden's Cannabis Stance
• UnitedHealthcare Senior Atty Joins Centivo As 1st GC
• AIG Unit Owes Coverage For Illinois Toxic Emissions Suits
• Combating Implicit Bias In Alternative Dispute Resolution
• Jones Day Adds Biotech Pro From Baker Botts In NY
• GenapSys Founders Win Delay On Bankruptcy Sale, Loan
• Robbins Geller Nabs $13.5M In Puma Biotech Investor Suit
• Arnold & Porter Names Head For New Amsterdam Office
• Patent Eligibility Bill May Clarify Law But Spur New Fights
• Monsanto Faces 1st Mo. Jury Over Roundup Users' Cancers
• Biden Issues Another Order To Protect Abortion Access
• Implant Co. Reaches $2M SEC Deal As Ex-CEO Stands Ground
• Ex-UChicago Professor Avoids Prison For Insider Trading
• These Abortion Ballot Measures Are Next After Kansas Vote
• How The Metaverse Will Affect Business And Legal Processes
• Steptoe & Johnson Adds Gov't Contracts Partner
• Bayer, Buyers Get Go-Ahead On $2.3M Sunscreen Settlement
• Eli Lilly Must Pay $61M For False Medicaid Rebate Calculation
• Cannabis Grower Wants Out Of Ark. THC Potency RICO Suit
• AstraZeneca, Bristol Myers, McKesson Snag Early Win In MDL
• Eli Lilly 'Proud' Of Drug Rebate Specialist's Process
• Sofia Vergara's Ex Tells Panel Jury Should Hear Embryo Suit
• 3rd Circ. Won't Increase Prison Term For GSK Researcher
• This Week's Regulatory Hires Span Finance, Gaming, Health
• Attorneys Get $13M In Fees For Mallinckrodt Securities Deal
• Trans W.Va. Medicaid Participants Win Bias Suit
• W.Va. County Appeals Opioid Bellwether Ruling
• Biotech Co. Sironax Raises $200M In Series B Funding
• DOJ's Fraud-On-The-FDA Liability Theory Is Problematic
• Mylan Asks 3rd Circ. To Uphold Win In $50M Tax Fight
• J&J Should Get $18M For 'Horrific' Counterfeits, Judge Says
• Garland Outlines Abortion Protections In New Post-Dobbs Suit
• Kirkland-Led KKR Sells Rubber, Plastics Biz In $950M Deal
• Merck Blasts Teen's Gardasil Suit As 'Anti-Vaxxer' Rhetoric
• Cooley Reps VC Firm On $122M Cancer Medicine Co. Funding
• What Cannabis Cos. Can Expect If Broadcast Ad Bill Passes
• Cherokee Say Okla. Court Should Proceed With Opioid Suit
• Monsanto Looks To Undo 11th Circ. Roundup Ruling
• W.Va. AG Inks $400M Deal With Drug Distributors Over Opioids
• Product Liability Cases To Watch: Midyear Review
• Biopharma Co. Board Sued In Del. For Blocking Director Slate
• 11th Circ. Won't Revive Investor Suit Against Med Tech Co.
• ​​​​​​​Gov't Contracts Of The Month: Internet In Space, Fall Vaccines
• 7th Circ. Declines To Revive Humira 'Patent Thicket' Claims
• Boston Scientific To Pay $85M To End Nevro Patent Litigation
• Imminent Tillis Bill Expands Eligibility, Protects Diagnostics
• Gordon & Rees Hires Health Care Partners For Raleigh Office
• Navigating Arbitral Subpoenas In A Post-COVID Landscape
• Judge Won't Toss $950M COVID-19 Vax Trade Secrets Row
• Prepare For Scrutiny In Marketing Contraception After Dobbs
• WilmerHale, Simpson Drive $2.45B Deal For PerkinElmer Units
• Pa. Panel Lets Hotel Next Door Set Pittsburgh Tower's Height
• Hospital Strikes $10.3M Deal In Religious Workers' Vax Suit
• Winston & Strawn Health Care Co-Chair Joins DOJ
• Bristol-Myers Says Its Former Lawyer Can't Testify In IP Battle